The DPP4 inhibitor sitagliptin demonstrates remarkable efficacy in animal studies, not only increasing embryo implantation rates in HD DHEA-induced rats but also significantly improving endometrial receptivity, providing substantial evidence for its potential clinical translation in PCOS-related infertility treatment. The gene discussed is DPP4; the disease is polycystic ovary syndrome.